A Novel Thromboxane Receptor Antagonist and Synthase Inhibitor, Bm-573, Reduces Development and Progression of Atherosclerosis in Ldl Receptor Deficient Mice.
From: Division of Cardiology, Washington University, Saint Louis, MO 63110, USA.
European journal of pharmacology
- Publish Date: Apr 2007
- ISSN: 0014-2999
- Volume: 561
- Issue: 1-3
- Pages: 105-11
- Medium: Print
- Language: English
- Citation (JAMA): Cyrus Tillmann, Yao Yuemang, Ding Tao, et al. A Novel Thromboxane Receptor Antagonist and Synthase Inhibitor, Bm-573, Reduces Development and Progression of Atherosclerosis in Ldl Receptor Deficient Mice.. Eur. J. Pharmacol. Apr 2007;561:105-11
Abstract
Atherosclerosis is a chronic inflammatory disease of the vasculature influenced by a variety of mediators. Among them, prostanoids, which include prostacyclin and thromboxane (Tx) A(2), have recently received a lot of attention. Previous studies demonstrated that antagonism or deletion of the receptor for TxA(2) retards early atherogenesis in apolipoprotein E-deficient mice, but no data are available in low-density lipoprotein (LDL) receptor deficient mice. In our study, we tested the effect of a novel TxA(2) receptor (TP) antagonist and synthase inhibitor, BM-573, on atherosclerosis development and progression in LDL receptor deficient mice. To this end, the effect of 12 weeks treatment with BM-573 on early or established aortic atherosclerotic lesions of these mice was assessed. In both treatments, while BM-573 did not affect body weight, systolic blood pressure, total plasma cholesterol or triglycerides levels, it partially reduced TxA(2) but did not affect prostacyclin biosynthesis. Moreover, BM-573 significantly decreased early atherogenesis and prevented progression of established atherosclerotic lesions. These results show for the first time that this dual Tx inhibitor is effective in reducing atherogenesis in the LDL receptor deficient mice. They also demonstrate the novel concept that this therapeutic approach halts the progression of the disease and influences the cellular composition of the atherosclerotic plaques.
Mesh Headings (Keywords): Animals, Aorta, Atherosclerosis, Blood Pressure, Body Weight, Cholesterol, Disease Models, Animal, Disease Progression, Epoprostenol, Male, Mice, Mice, Inbred C57BL, Platelet Aggregation Inhibitors, Receptors, LDL, Receptors, Thromboxane, Sulfonylurea Compounds, Thromboxane A2, Triglycerides
Check for Full Text / PubMed Unique Identifier (PMID): 17306791
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.